206 related articles for article (PubMed ID: 38616443)
1. Systemic Therapy Advances for HER2-Positive and Triple Negative Breast Cancer: What the Surgeon Needs to Know.
Downs-Canner S; Weiss A
Clin Breast Cancer; 2024 Jun; 24(4):328-336. PubMed ID: 38616443
[TBL] [Abstract][Full Text] [Related]
2. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
[TBL] [Abstract][Full Text] [Related]
3. The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial.
Yamaguchi T; Hozumi Y; Sagara Y; Takahashi M; Yoneyama K; Fujisawa T; Osumi S; Akabane H; Nishimura R; Mieno MN; Mukai H
Surg Oncol; 2021 Mar; 36():51-55. PubMed ID: 33310293
[TBL] [Abstract][Full Text] [Related]
4. Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction.
Samiei S; van Kaathoven BN; Boersma L; Granzier RWY; Siesling S; Engelen SME; de Munck L; van Kuijk SMJ; van der Hulst RRJW; Lobbes MBI; Smidt ML; van Nijnatten TJA
Ann Surg Oncol; 2019 Nov; 26(12):3902-3909. PubMed ID: 31359276
[TBL] [Abstract][Full Text] [Related]
5. The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer.
Leon-Ferre RA; Hieken TJ; Boughey JC
Ann Surg Oncol; 2021 Apr; 28(4):2111-2119. PubMed ID: 33486641
[TBL] [Abstract][Full Text] [Related]
6. De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study.
Simons JM; Koppert LB; Luiten EJT; van der Pol CC; Samiei S; de Wilt JHW; Siesling S; Smidt ML
Breast Cancer Res Treat; 2020 Apr; 180(3):725-733. PubMed ID: 32180074
[TBL] [Abstract][Full Text] [Related]
7. Omission of breast surgery in selected breast cancer patients with excellent response to neoadjuvant systemic therapy.
Tasoulis MK; Muktar S; Smith I; Roche N; MacNeill F
Eur J Surg Oncol; 2024 Jun; 50(6):108277. PubMed ID: 38522333
[TBL] [Abstract][Full Text] [Related]
8. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?
Okamoto S; Yamada T; Kanemaki Y; Kojima Y; Tsugawa K; Nakajima Y
Breast Cancer; 2016 Sep; 23(5):789-96. PubMed ID: 26437647
[TBL] [Abstract][Full Text] [Related]
10. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy for triple-negative and Her2 +ve breast cancer: striving for the standard of care.
Roberts A; Hallet J; Nguyen L; Coburn N; Wright FC; Gandhi S; Jerzak K; Eisen A; Look Hong NJ
Breast Cancer Res Treat; 2024 Jul; 206(2):227-244. PubMed ID: 38676808
[TBL] [Abstract][Full Text] [Related]
12. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.
Kuerer HM; Smith BD; Krishnamurthy S; Yang WT; Valero V; Shen Y; Lin H; Lucci A; Boughey JC; White RL; Diego EJ; Rauch GM;
Lancet Oncol; 2022 Dec; 23(12):1517-1524. PubMed ID: 36306810
[TBL] [Abstract][Full Text] [Related]
13. Emerging strategies in neoadjuvant treatment of patients with HER2-positive early breast cancer.
Harbeck N
Breast; 2019 Nov; 48 Suppl 1():S97-S102. PubMed ID: 31839172
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.
Harbeck N
Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S12-S16. PubMed ID: 35148934
[TBL] [Abstract][Full Text] [Related]
15. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint.
Johnson HM; Valero V; Yang WT; Smith BD; Krishnamurthy S; Shen Y; Lin H; Lucci A; Rauch GM; Kuerer HM
J Am Coll Surg; 2023 Jul; 237(1):101-108. PubMed ID: 36856291
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant therapy for triple negative and HER2-positive early breast cancer.
Harbeck N; Gluz O
Breast; 2017 Aug; 34 Suppl 1():S99-S103. PubMed ID: 28666920
[TBL] [Abstract][Full Text] [Related]
18. Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).
Golshan M; Cirrincione CT; Sikov WM; Carey LA; Berry DA; Overmoyer B; Henry NL; Somlo G; Port E; Burstein HJ; Hudis C; Winer E; Ollila DW;
Breast Cancer Res Treat; 2016 Nov; 160(2):297-304. PubMed ID: 27704226
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer.
Nakatsukasa K; Koyama H; Oouchi Y; Imanishi S; Mizuta N; Sakaguchi K; Fujita Y; Fujiwara I; Kotani T; Matsuda T; Fukuda K; Morita M; Kawakami S; Kadotani Y; Konishi E; Yanagisawa A; Taguchi T
Breast Cancer; 2017 Jan; 24(1):63-68. PubMed ID: 26754092
[TBL] [Abstract][Full Text] [Related]
20. Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy.
Sun S; van la Parra RFD; Rauch GM; Checka C; Tadros AB; Lucci A; Teshome M; Black D; Hwang RF; Smith BD; Krishnamurthy S; Valero V; Yang WT; Kuerer HM
Ann Surg Oncol; 2019 Oct; 26(10):3071-3079. PubMed ID: 31342361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
